Onderneming Opexa Therapeutics Inc Nasdaq
Aandelen
US68372T2024
Biotechnologie & Medisch Onderzoek
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
R. Clifton
DFI | Director of Finance/CFO | 51 | 17/11 |
Tanya Hayden
COO | Chief Operating Officer | 44 | 01-06-21 |
John M. Klopp
CTO | Chief Tech/Sci/R&D Officer | 50 | - |
Jim DeNike
IRC | Investor Relations Contact | - | - |
Bernie Paul
HRO | Human Resources Officer | 65 | 01-05-19 |
Renee Carroll
LAW | General Counsel | - | 01-01-20 |
Jason Kneeland
AUD | Comptroller/Controller/Auditor | - | 01-11-17 |
Kim Tharaldsen
SAM | Sales & Marketing | - | 05-02-18 |
Corporate Officer/Principal | 57 | 01-12-13 | |
Donald Joseph
LAW | General Counsel | 70 | 01-04-18 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
R. Clifton
DFI | Director of Finance/CFO | 51 | 17/11 |
Joshua Schafer
BRD | Director/Board Member | 53 | 17/11 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 24 463 726 | 24 463 726 ( 100,00 %) | 0 | 100,00 % |
Bedrijfsgegevens
![Adres Opexa Therapeutics Inc](https://cdn.zonebourse.com/static/address/12191752.png)
Sector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+15,58% | 121 mld. | |
+16,60% | 110 mld. | |
+18,78% | 25,93 mld. | |
-24,33% | 19,27 mld. | |
-19,51% | 16,01 mld. | |
-17,95% | 15,66 mld. | |
-46,81% | 14,89 mld. | |
+58,78% | 14,47 mld. | |
+4,91% | 13,91 mld. |